What is Tacholiquin?
Tacholiquin, a sterile solution administered via inhalation since 1960 in Europe is currently available in Malaysia and South East Asia. Meet the key to keep breathing freely without affecting your respiratory muco-clearance physiological mechanism. Tacholiquin has been scientifically proven to break and expectorate sputum and provide relief from heavy chest.
Why we made Tacholiquin for you?
Unmet need for mucolytics that promote sputum expectoration
No single supportive therapy effective across the symptom of mucus obstructive conditions in respiratory diseases
Mucolytic in inhalation form that directly work on the respiraty tract to liquify sputum
Need for mucolytic with anti-inflammatory properties
Tacholiquin is convenient because..
Indications
Used for inhalation as adjunct or supportive treatment for various disease of the respiratory tract associated with thick sputum formation.
Liquify and encourage infectious ejection of sputum and reduce airway obstruction from excess mucus plugging via physical mechanism.
Helps to restore normal activity of cilia for self-cleaning function which are inhibited by excess mucus production.
Tacholiquin is suitable for
people with respiratory diseases or/and muco-obstructive diseases such as:
Cystic Fibrosis
Tracheostomy patient
Chronic Cough
COPD
Chronic sinusitis
Chronic Bronchitis
Post infection wet cough
Tacholiquin is suitable for
people with respiratory diseases or/and muco-obstructive diseases such as:
Cystic Fibrosis
Tracheostomy patient
Chronic Cough
COPD
Chronic sinusitis
Chronic Bronchitis
Post infection wet cough
Mode of Action
Study findings of Tacholiquin
Tyloxapol is very effective and approved as a mucolytic
Tyloxapol shows a significant bronchodilation effect compared to saline
Inhalation of Tyloxapol in patients with COPD is safe and superior to saline and shows anti-inflammatory effects
References:
1. Koppitz M, Eschenburg C, Salzmann E, Rosewich M, Schubert R, Zielen S. (2016). Mucolytic Effectiveness of Tyloxapol in Chronic Obstructive Pulmonary Disease - A Double-Blind, Randomized Controlled Trial. PLoS One.
2. Beubler E, Fischer R, Untersteiner G, Wolfgang S. (2016). Influence of the Surfactant Tyloxapol on Mucociliary Clearance in Human Respiratory Cystic Fibrosis Cells. Pharmacology, 98(1-2), 1-3.
3 .Tainter M, Nachod F, Bird J. (1955). Alevaire as a Mucolytic Agent. The New England Journal of Medicine.
Study findings of Tacholiquin
Tyloxapol is very effective and approved as a mucolytic
Tyloxapol shows a significant bronchodilation effect compared to saline
Inhalation of Tyloxapol in patients with COPD is safe and superior to saline and shows anti-inflammatory effects
References:
1. Koppitz M, Eschenburg C, Salzmann E, Rosewich M, Schubert R, Zielen S. (2016). Mucolytic Effectiveness of Tyloxapol in Chronic Obstructive Pulmonary Disease - A Double-Blind, Randomized Controlled Trial. PLoS One.
2. Beubler E, Fischer R, Untersteiner G, Wolfgang S. (2016). Influence of the Surfactant Tyloxapol on Mucociliary Clearance in Human Respiratory Cystic Fibrosis Cells. Pharmacology, 98(1-2), 1-3.
3 .Tainter M, Nachod F, Bird J. (1955). Alevaire as a Mucolytic Agent. The New England Journal of Medicine.